目的 探讨降糖宁胶囊联合罗格列酮治疗2型糖尿病的临床效果。方法 选取2018年6月—2021年6月在商洛市中心医院接受治疗的98例2型糖尿病患者，按随机数字表法将患者分为对照组和治疗组，每组各49例。对照组口服盐酸罗格列酮胶囊，4 mg/d，顿服。治疗组在对照组治疗基础上口服降糖宁胶囊，2 g/次，3次/d。两组疗程12周。评估两组降糖疗效，对比治疗前后两组餐后2 h血糖（2 h PG）等糖代谢指标、胰岛功能指标[胰岛β细胞功能指数（HOMA-β）、胰岛素抵抗指数（HOMA-IR）]、血小板最大聚集率（MAR）、血液流变学参数[血浆黏度（PV）、全血高切黏度（HBV）、全血低切黏度（LBV）]及血清视黄醇结合蛋白4（RBP4）、可溶性细胞间黏附分子1（sICAM-1）、脂联素（APN）、生长分化因子-15（GDF-15）水平。结果 治疗后，治疗组总有效率是95.9%，显著高于对照组的83.7%（P＜0.05）。治疗后，两组患者FPG、2 h PG、HbA1c均显著降低（P＜0.05）；治疗后，治疗组糖代谢指标低于对照组（P＜0.05）。治疗后，两组HOMA-β显著升高，而HOMA-IR显著降低（P＜0.05）；治疗后，治疗组胰岛功能指标改善优于对照组（P＜0.05）。与治疗前比较，两组治疗后MAR和血液流变学参数（PV、HBV、LBV）均显著降低（P＜0.05）；且均以治疗组下降更显著（P＜0.05）。治疗后，两组血清RBP4、sICAM-1和GDF-15浓度均较治疗前显著下降，而血清APN水平均较治疗前显著升高（P＜0.05）；且治疗后，治疗组血清RBP4、sICAM-1、APN和GDF-15水平改善较对照组更显著（P＜0.05）。结论 降糖宁胶囊联合罗格列酮治疗2型糖尿病能获得较为理想的血糖控制效果，并可进一步改善胰岛功能及机体微循环，增强内源性保护作用，保护血管内皮功能，且安全性好，值得临床推广应用。

Objective To explore the clinical effect of Jiangtangning Capsules combined with rosiglitazone in treatment of type 2 diabetes. Methods 98 Patients with type 2 diabetes who received treatment in Shangluo Central Hospital from June 2018 to June 2021 were selected and divided into control group and treatment group according to random number table method, with 49 cases in each group. Patients in the control group were po administered with Rosiglitazone Hydrochloride Capsules, 4 mg/d, and was given daily. Patients in the treatment group were po administered with Jiangtangning Capsules on the basis of the control group, 2 g/time, 3 times daily. Both groups were treated for 12 weeks. After treatment, the clinical efficacy was evaluated, 2 h PG and other glucose metabolism indicators, HOMA-β, HOMA-IR, MAR, PV, HBV, LBV, RBP4, sICAM-1, APN, GDF-15 in two groups before and after treatment were compared.Results After treatment, the total effective rate of the treatment group was 95.9%, which was significantly higher than that of the control group (83.7%, P < 0.05). After treatment, FPG, 2 h PG, and HbA1c were significantly decreased in both groups (P < 0.05). After treatment, the glucose metabolism index of the treatment group was lower than that of the control group (P <0.05). After treatment, HOMA-β was significantly increased, while HOMA-IR was significantly decreased in both groups (P < 0.05). After treatment, the improvement of islet function indexes in treatment group was better than that in control group (P < 0.05). Compared with before treatment, MAR and hemorheological parameters (PV, HBV, LBV) were significantly decreased in both groups after treatment (P < 0.05). The decrease was more significant in the treatment group (P < 0.05). After treatment, serum concentrations of RBP4, sICAM-1, and GDF-15 in both groups were significantly decreased compared with before treatment, but serum APN levels were significantly increased compared with those before treatment (P < 0.05). After treatment, the serum levels of RBP4, sICAM-1, APN, and GDF-15 in treatment group were significantly improved compared with those in the control group (P < 0.05). Conclusion Jiangtangning Capsules combined with rosiglitazone can obtain ideal blood glucose control effect in treatment of type 2 diabetes, and can further improve islet function and microcirculation, enhance endogenous protective effect, and protect vascular endothelial function, which is safe and worthy of clinical application.

R977